Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

NCT00123461 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hyperparathyroidism
Renal Failure
Chronic Renal Insufficiency

Interventions

DRUG: Hectorol (doxercalciferol capsules), 0.5mcg

Sponsor

Genzyme, a Sanofi Company